This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Genzyme Corporation. Active years: 2022.
Company Filing History:
Years Active: 2022
Title: Yves Sabbagh: Innovator in FGFR3 Antibodies
Introduction
Yves Sabbagh is a notable inventor based in Framingham, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of antibodies targeting FGFR3. His work has implications for treating various diseases and disorders associated with this receptor.
Latest Patents
Yves Sabbagh holds a patent for FGFR3 antibodies and methods of use. This patent includes anti-FGFR3 antigen-binding proteins and their binding fragments. Additionally, it outlines methods for inhibiting FGFR3 activity and treating FGFR3-mediated diseases and disorders.
Career Highlights
Yves Sabbagh is currently associated with Genzyme Corporation, a leading biotechnology company. His role at Genzyme has allowed him to focus on innovative solutions in the medical field, particularly in the area of targeted therapies.
Collaborations
Throughout his career, Yves has collaborated with esteemed colleagues such as Yangde Chen and William Harold Brondyk. These partnerships have fostered a collaborative environment that enhances research and development efforts.
Conclusion
Yves Sabbagh's contributions to the field of FGFR3 antibodies exemplify the impact of innovative research in biotechnology. His work continues to pave the way for advancements in treating related diseases and disorders.